ETX.L Share News (ETX)
ETX Share
ETX Share
ETX Share
ETX Share
ETX
ETX Share
ETX Broker
ETX Directors
ETX Financial
ETX
ETX Short
ETXWed, 08th Jul 2020 16:21
e-Therapeutics PLC - Oxford-based drug discovery platform - Raises GBP750,000 in retail offer as part of GBP12.4 million fundraise announced on Tuesday.
Current stock price: 12.87 pence
Year-to-date change: up more than fivefold from 3.10p
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps E-THERAPEUTICS PLC (ETX.LN), a U.K. drug developer, said Tuesday its focus this year and next will be on clinical trials of its experimental medicines an
Read moreBy Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--U.K. drug developer e-Therapeutics PLC (ETX.LN) Tuesday said its focus this year and next will be on clinical trials of its experimental medicines and securing alliances with pharmaceutical companies. E-Therapeutics, which uses
Read moreSupport services group Northern Bear stretched its strong run Tuesday after claiming a good start to the new financial year, with its order book and pipeline well up on a year ago. "The board is pleased to announce that the new financial year has started well, with strong order books and a healthy
Read moreLONDON (Dow Jones)--Drug discovery company e-Therapeutics PLC (ETX.LN) Tuesday reported a wider fiscal-year loss and said it remains in talks with drug makers about commercial collaborations. E-Therapeutics, which uses computer software to develop new drugs, added the first of several planned Ph
Read moreRedrow chairman Steve Morgan's wife has bought 100,000 shares in the housebuilder taking their combined stake to 29.95%. Fiona Morgan paid 131.5p a share for the 100,000 shares. The total cost was £131,500. Morgan founded Redrow in 1974 and floated the company 20 years later. He also owns Wolver
Read moreDrug discovery and development company e-Therapeutics said annual losses narrowed and it remains confident of becoming cash generative. For the year ended 31 January loss before tax narrowed to £1.96m from a loss of £2.2m the year before. Revenue increased to £67,000 from £64,000 the previous year.
Read more
